InfuSystem Holdings, Inc. (INFU) Fair Value 2026

INFU · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.1 /10

32 fundamental signals · 11 models active

Value Trap Risk

SAFE (12/100)

Quick Summary — As of 2026-08-27, InfuSystem Holdings, Inc. (INFU) trades at $12.06, versus a $10.10 median fair value across its 11 active models — 16.2% below the current price. QOC: 8.1/10. Value Trap Risk: 12/100 (SAFE). 11/13 models active. Within that set, the Bayesian DCF component alone returns $11.96.

Key Facts

Ticker
INFU
Price
$12.06
Quality Score
8.1/10
Value Trap Risk
12/100
Models Active
11/13
Last Updated
Strength: First Chicago suggests +207.4% upside with 63% confidence
Risk: Majority of models suggest overvaluation

Is InfuSystem Holdings, Inc. (INFU) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, InfuSystem Holdings, Inc. (INFU) appears overvalued as of : the median of 11 independent fair value estimates is $10.10, 16.2% below the current price of $12.06. Estimates range from $0.39 to $37.07. INFU scores 8.1/10 on fundamental quality and 12/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. INFU’s -16.2% gap is narrower than that market norm, and the Medical Devices sector median is -43.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy InfuSystem Holdings, Inc. Stock in 2026? →

What Fair Value Does Each Model Give INFU?

11 Intrinsic Value Models vs. Current Price ($12.06)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $11.96 -0.8%
Intrinsic · High Conviction
 $0.39 -96.8%
Ensemble · Low Conviction
 $9.98 -17.2%
Scenario · High Conviction
 $37.07 +207.4%
Unlock the Full Matrix

Access 7 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is INFU's Fair Value Range?

Spread across 11 independent models · $0.39 to $37.07

CirclFi's 11 active models place InfuSystem Holdings, Inc. (INFU) between $0.39 and $37.07 per share, a spread of 363% of the median. The median of that range — $10.10 — is the fair value CirclFi publishes for INFU, against a current price of $12.06.

Low · EPVHigh · First Chicago
$0.39median $10.10$37.07
Where the range comes from
Most bearish modelEarnings Power Value (EPV)$0.39
Most bullish modelFirst Chicago$37.07
Model agreement4 bullish · 6 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for INFU. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on INFU, not a CirclFi price target. How each model works →

What Is InfuSystem Holdings, Inc. (INFU) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, InfuSystem Holdings, Inc.'s intrinsic value is estimated at a median $10.10, showing conflicting signals at the current price of $12.06. While the median implied return is -16.2%, model disagreement is elevated with a gap of +304.1% between the most bullish and bearish estimates. The most optimistic model, First Chicago, places fair value at $37.07 (+207.4%), while EPV — the most conservative — estimates $0.39 (-96.8%). This +304.1% gap reflects genuine analytical uncertainty about InfuSystem Holdings, Inc.'s intrinsic worth. Among models with highest confidence, Bayesian DCF, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About INFU?

11 of 13 models are currently active for INFU. Of these, 4 models suggest upside while 7 models suggest overvaluation. Taken together, their median fair value for INFU is $10.10 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $11.96 on its own, implying -0.8% downside from the current price. See which stocks rank higher →

How Does INFU Rank in Medical Devices?

Among 157 Medical Devices stocks, INFU ranks #28 by Quality of Company score. CirclFi's QOC score of 8.1/10 evaluates 32 fundamental signals. A score of 8.1 places INFU in the top tier.

See all Most Undervalued Medical Devices Stocks →

InfuSystem Holdings, Inc.'s positioning within the Medical Devices segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including therapeutic area leadership — shape both the opportunity set and risk profile.

Is INFU a Value Trap?

CirclFi's Value Trap algorithm assigns INFU a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for InfuSystem Holdings, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, InfuSystem Holdings, Inc. earns a quality score of 8.1/10. This robust rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +304.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every INFU valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across INFU's 11 active models, average confidence is 50%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy InfuSystem Holdings, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

LIVNLivaNova PLCQOC 8.1GEHCGE HealthCare Technologies Inc.QOC 7.9VMDViemed Healthcare, Inc.QOC 8.1MDTMedtronic plcQOC 7.8ITGRInteger Holdings CorporationQOC 8.2BIOBio-Rad Laboratories, Inc.QOC 7.8SERASera Prognostics, Inc.QOC 6.6LFWDLifeward Ltd.QOC 5.6MOBIMobia Medical, Inc.QOC 3.9IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: LIVN · GEHC · VMD · MDT · ITGR · BIO · SERA · LFWD · MOBI · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to INFU?

7 companies across all industries closest to INFU’s Quality of Company score of 8.1/10.

PAGPenske Automotive Group, Inc.QOC 8.1JANLJanel CorporationQOC 8.1TREXTrex Company, Inc.QOC 8.1CCSIConsensus Cloud Solutions, Inc.QOC 8.1VNTVontier CorporationQOC 8.1PCYOPure Cycle CorporationQOC 8.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: PAG · JANL · TREX · CCSI · VNT · PCYO · NVDA

Where Does INFU Sit in CirclFi's Medical Devices Rankings?

INFU is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About InfuSystem Holdings, Inc.’s Valuation?

What is InfuSystem Holdings, Inc.'s intrinsic value in 2026?

CirclFi puts InfuSystem Holdings, Inc. (INFU)'s intrinsic value at $10.10 — the median of 11 independent model estimates as of 2026-08-27, ranging from $0.39 to $37.07. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $11.96 on its own. The Quality of Company score is 8.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is INFU overvalued or undervalued right now?

At $12.06, 4 of 11 active models suggest INFU may be undervalued, while 7 indicate potential overvaluation. The median of all 11 fair value estimates is $10.10, 16.2% below the current price of $12.06 — a consensus view that INFU is overvalued. The assessment depends on which methodology best fits InfuSystem Holdings, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 8.1 mean for INFU?

InfuSystem Holdings, Inc.'s QOC of 8.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on INFU?

CirclFi analyzes INFU with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on INFU?

Of the 11 models currently active on INFU, First Chicago is the most bullish at $37.07 per share, and Earnings Power Value (EPV) is the most bearish at $0.39. CirclFi's published fair value for INFU is the median of that range, $10.10, not either extreme. The gap between the two ends equals 363% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is INFU a value trap in 2026?

InfuSystem Holdings, Inc.'s Value Trap score is 12/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 11-model valuation engine, InfuSystem Holdings, Inc. (INFU) has a median fair value of $10.10 — 16.2% below the current price of $12.06 — as of 2026-08-27.” Source: circlfi.com/stock/INFU/ · Methodology
Primary sources for this INFU valuation
  • Financial statements: InfuSystem Holdings, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001337013) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for INFU as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on INFU.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

7 models hidden for INFU Unlock All 11 — $39/mo